News Focus
News Focus
Followers 5
Posts 3948
Boards Moderated 0
Alias Born 03/21/2024

Re: seekinganswers post# 785806

Wednesday, 09/03/2025 11:14:32 AM

Wednesday, September 03, 2025 11:14:32 AM

Post# of 802938
Agreed. Even UK approval won’t move the needle as I have been saying all along because shorts and markets know that they won’t be able to execute on commercialization plans in a reasonable time frame. It’s already taken 5 long years to get to this point so no one is going to trust them with the next phase. In fact, it’s extremely clear they are not positioned for those next steps - no hiring, no reimbursement evidence submission, etc. These processes start at least 6-9 months before approval regardless of how big or small the biotech company is so they can hit the ground running. But then the excuses will pour in from minions when the market response is muted and shorts slam the stock on any brief upside we may get whenever there is UK approval PR in 2026.

It will be similar to what we just observed with the Advent PR and not much different from what we had seen with JAMA, MIA, Nature, etc. Only shorts and LP’s financiers make money consistently in this dilution scam.

Overall, it all boils down to significant non dilutive funding from a big pharma partner who not only stops the bleeding (dilution) but more importantly lends credibility and a realistic chance of acquisition down the road. Unfortunately, this ain’t happening! ;)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News